Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonlinear ethotoin kinetics.

M C Meyer, B J Holcombe, G J Burckart

    Clinical Pharmacology and Therapeutics
    |March 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response to Comment on "Permanent human occupation of the central Tibetan Plateau in the early Holocene".

    Science (New York, N.Y.)·2017
    Same author

    Response to Comment on "Permanent human occupation of the central Tibetan Plateau in the early Holocene".

    Science (New York, N.Y.)·2017
    Same author

    Evaluation of the Safety of Drugs and Biological Products Used During Lactation: Workshop Summary.

    Clinical pharmacology and therapeutics·2017
    Same author

    Permanent human occupation of the central Tibetan Plateau in the early Holocene.

    Science (New York, N.Y.)·2017
    Same author

    Mapping transmembrane residues of proteinase activated receptor 2 (PAR<sub>2</sub>) that influence ligand-modulated calcium signaling.

    Pharmacological research·2016
    Same author

    The Influence of Race and Common Genetic Variations on Outcomes After Pediatric Heart Transplantation.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    This study investigated ethotoin pharmacokinetics in healthy subjects. Higher doses led to slower absorption and nonlinear elimination, with adverse effects observed at elevated ethotoin levels.

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy
    • Drug Metabolism

    Background:

    • Ethotoin is an anticonvulsant medication.
    • Understanding ethotoin's dose-dependent behavior is crucial for safe and effective therapeutic use.

    Purpose of the Study:

    • To characterize the pharmacokinetic profile of ethotoin following single oral doses.
    • To evaluate the dose proportionality and elimination kinetics of ethotoin.
    • To assess the relationship between ethotoin plasma concentrations and observed adverse effects.

    Main Methods:

    • Healthy subjects received single oral doses of ethotoin (500, 1500, 2500 mg) at 7-day intervals.
    • Plasma ethotoin concentrations were measured using High-Performance Liquid Chromatography (HPLC) over 49 hours post-dose.
    • Pharmacokinetic parameters were analyzed using first-order and Michaelis-Menten models.

    Related Experiment Videos

    Main Results:

    • Ethotoin absorption was slower at higher doses (1500 and 2500 mg).
    • Area Under the Curve (AUC) increased disproportionately with escalating doses, indicating nonlinear pharmacokinetics.
    • The Michaelis-Menten model best described ethotoin elimination in most subjects (11 out of 15 datasets).
    • Adverse effects, including visual disturbances and gait dyscoordination, were reported at higher doses.

    Conclusions:

    • Ethotoin exhibits dose-dependent absorption and nonlinear elimination kinetics.
    • The observed adverse effects at higher ethotoin doses may not be directly correlated with plasma concentrations.
    • Further research is warranted to elucidate the mechanisms behind ethotoin's nonlinear behavior and associated toxicities.